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Abstract
Background: There are few studies to demonstrate the associations between newly addressed lipid profiles and
metabolic syndrome (MetS)-associated variables.
Methods: Study participants without medications for hypertension, diabetes, or dyslipidemia {614 men aged 58 ±
14 (mean ± standard deviation; range, 20-89) years and 779 women aged 60 ± 12 (range, 21-88) years} were
randomly recruited from a single community at the time of their annual health examination. The association
between lipid profiles (total cholesterol (T-C), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), non-HDL-C, T-C/HDL-C, TG/HDL-C, LDL-C/HDL-C ratio and MetS, Insulin
resistance by homeostasis model assessment of insulin resistance (HOMA-IR), and serum HMW adiponectin were
analyzed.
Results: In multiple linear regression analysis, TG/HDL-C and T-C/HDL-C ratios as well as TG showed significantly
strong associations with all three MetS-associated variables in both men and women. In men, the ROC curve
analyses showed that the best marker for these variables was TG/HDL-C ratio, with the AUC for presence of MetS
(AUC, 0.82; 95% CI, 0.77-0.87), HOMA-IR (AUC, 0.75; 95% CI, 0.70-0.80), and serum HMW adiponectin (AUC, 0.67; 95%
CI, 0.63-0.71), respectively. The T-C/HDL-C ratio, TG, HDL-C, LDL-C/HDL-C ratio, and non-HDL-C also discriminated
these markers; however all their AUC estimates were lower than TG/HDL-C ratio. These results were similar in
women.
Conclusion: In Japanese community-dwelling adults, lipid ratios of TG/HDL-C, T-C/HDL-C, LDL-C/HDL-C as well as
TG and HDL-C were consistently associated with MetS, insulin resistance and serum HMW adiponectin. Lipid ratios
may be used as reliable markers.
Background
Metabolic syndrome (MetS) known as a clustering of
cardiovascular risk factors associated with insulin resis-
tance, hypertension, glucose intolerance, hypertriglyceri-
demia [1,2], and low levels of high-density lipoprotein
cholesterol (HDL-C), is a major worldwide public health
problem. In Japan also, MetS is quite common, affecting
13.3% to 25.3% of Japanese men [3,4] and may become
even more common in the future with the continuous
increase in the prevalence of obesity. Several epidemio-
logical studies have demonstrated that MetS increases
the risk of various cardiovascular diseases (CVD) [5]
and diabetes [6].
Serum adiponectin, which is a 247-amino acid protein
secreted specifically by adipose tissue, contains four dif-
ferentiable domains that regulate lipid metabolism, glu-
cose metabolism, and insulin sensitivity [7], and low
circulating levels of serum adiponectin has been
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bolic syndrome [8] and CVD [9]. The high molecular
weight (HMW) form binds most avidly to its receptors
and is one of the important molecules activating meta-
bolic role of adiponectin [10].
Dyslipidemia is another well-known risk factor for
CVD, as well as a component of MetS, and the role of
HDL-C, triglycerides (TG) and low-density lipoprotein
cholesterol (LDL-C) are already established as predictors
of CVD [11]. On the other hand, a characteristic dyslipi-
demia is also associated with insulin resistance [12]. Sev-
eral studies have reported the possibility that newly
addressed lipid profiles might be more useful than the
traditional ones used for CVD prediction, and measur-
ing these variables might help identify insulin resistance
and CVD [13]. Total cholesterol (T-C)/HDL-C, TG/
HDL-C, and LDL-C/HDL-C ratio [13-15], as well as TG
and HDL-C [16] are independently associated with insu-
lin resistance and risk factors of CVD. However, in Japa-
nese community-dwelling persons, there are few studies
to demonstrate the associations between these lipid pro-
files, especially the lipid ratios, with MetS, insulin resis-
tance and serum HMW adiponectin.
We took advantage of the large representative sample
of Japanese adults who participated at the time of their
annual health examination. We investigated how lipid
profiles were associated with MetS, insulin resistance
and serum HMW adiponectin in healthy Japanese
adults. For this, we used cross-sectional data from com-
munity-dwelling participants without medication and
clinical diabetes.
Methods
Subjects
Participants were recruited at the time of their annual
health examination. The sample population compro-
mised 3,164 middle-aged to elderly residents. Informa-
tion on medical history, present conditions, and drugs
were obtained by interview. Other characteristics, e.g.,
smoking and alcohol habits, and medication, were inves-
tigated by individual interviews using a structured ques-
tionnaire. Subjects taking medications for hypertension,
diabetes, or dyslipidemia were excluded. The final study
sample included 614 men and 779 women. This study
was approved by the ethics committee of Ehime Univer-
sity School of Medicine, and written informed consent
was obtained from each subject.
Evaluation of confounding factors
Information on demographic characteristics and risk fac-
tors was collected using clinical files. Body mass index
(BMI) was calculated by dividing weight (in kilograms)
by the square of the height (in meters). We measured
blood pressure in the right upper arm of participants in a
sedentary position using an automatic oscillometric
blood pressure recorder (BP-103i; Colin, Aichi, Japan)
while the subjects were seated after having rested for at
least 5 min. Smoking status was defined as the number of
cigarette packs per day multiplied by the number of years
smoked (pack · year), and the participants were classified
into never smokers, past smokers, light smokers (<30
pack · year) and heavy smokers (≥30 pack · year). The
daily alcohol consumption was measured using the Japa-
nese liquor unit in which a unit corresponds to 22.9 g of
ethanol, and the participants were classified into never
drinkers, occasional drinkers (<1 unit/day), light drinkers
(1-1.9 unit/day), and heavy drinkers (≥2 unit/day). T-C,
TG, HDL-C, fasting blood glucose (FBG), creatinine
(enzymatic method), immunoreactive insulin (IRI), and
serum HMW adiponectin (FUJIREBIO, Tokyo, Japan)
were measured during fasting. LDL-C levels were calcu-
lated using the Friedewald formula [17]. Participants with
TG levels ≥400 mg/dl were excluded. Homeostasis model
assessment of insulin resistance (HOMA-IR) was calcu-
lated from FBG and IRI levels using the following for-
mula; {FBG (mg/dL) × IRI (mU/mL)}/405 [18].
Metabolic Syndrome
We applied condition-specific cutoff points for MetS
based on the modified guidelines for the diagnosis of
MetS in Japan [19]. Metabolic syndrome was defined as
o b e s i t yw i t ha tl e a s tt w oo ft h ef o l l o w i n gt h r e ec o n d i -
tions: hypertension, dyslipidemia, and impaired fasting
glucose (IFG). Obesity was defined as a BMI of ≥25.0
kg/m
2 [20]. Hypertension was defined as systolic blood
pressure (SBP) ≥130 mmHg and diastolic blood pressure
(DBP) ≥85 mmHg. Dyslipidemia was defined as TG con-
centrations ≥150 mg/dL and low HDL cholesterolemia
(HDL-C <40 mg/dL). IFG was defined as a FBG level
≥110 mg/dL.
Statistical analysis
Statistical analysis was performed using PASW Statistics
17.0 (Statistical Package for Social Science Japan, Inc.,
Tokyo, Japan). All values are expressed as mean ± stan-
dard deviation (SD), unless otherwise specified. Data for
T G ,F B G ,H O M A - I R ,a n ds e r u mH M Wa d i p o n e c t i n
were skewed, and log-transformed for analysis. Differ-
ences between the two groups were determined by Stu-
dent’st - t e s ta n dc
2 test. Subjects were divided into four
groups based on the quartile of HOMA-IR and serum
HMW adiponectin levels and the cutoff points for meta-
bolic disorder were defined as the fourth quartile of
HOMA-IR and first quartile of serum HMW adiponec-
tin levels, respectively. Multiple linear regression analysis
was used to evaluate the contribution of each lipid
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and serum HMW adiponectin. In addition, areas under
the receiver operating characteristic (ROC) curves were
determined for each variable to identify the predictors
of MetS-associated variables. The area under the curve
(AUC) of ROC curves is a summary of the overall diag-
nostic accuracy of the test. The best markers have ROC
curves that are shifted to the left with areas under the
curve near unity. Nondiagnostic markers are represented
by diagonals with the AUC of ROC curves close to 0.5.
A value of P < 0.05 was considered significant.
Results
Background factors of subjects categorized by sex
Table 1 shows the value of each background factor cate-
gorized by sex. The subjects comprised 614 men aged
58 ± 14 (range, 20-89) years and 779 women aged 60 ±
12 (range, 21-88) years. The mean BMI was 23.3 ± 3.0
kg/m
2 and 22.9 ± 3.2 kg/m
2 in men and women, respec-
tively. BMI, smoking status, alcohol consumption, systo-
lic blood pressure (SBP), diastolic blood pressure (DBP),
TG, and TG/HDL-C ratio were significantly higher but
age, T-C, HDL-C, LDL-C, and Non-HDL-C were signifi-
cantly lower in men than in women. There were no
inter-group differences regarding T-C/HDL-C ratio,
LDL-C/HDL-C ratio, eGFR, and prevalence of CVD.
Insulin resistance of subjects categorized by sex
Prevalence of MetS and FBG were significantly higher in
m e nt h a ni nw o m e n ,b u tI R I ,H O M A - I Ra n ds e r u m
HMW adiponectin were significantly lower in men
(Table 2).
Synergistic effect of increased HOMA-IR and reduced
serum HMW adiponectin
Figure 1 showed synergistic effect of increased HOMA-
IR and reduced serum HMW adiponectin. Mean accu-
mulated number of MetS components was the highest
in the highest HOMA-IR-lowest serum HMW adiponec-
tin quartile group and lowest in the lowest HOMA-IR-
highest serum HMW adiponectin quartile group, while
HOMA-IR appears to be a more dominant determinant
for MetS components than serum HMW adiponectin.
HOMA-IR and serum HMW adiponectin were indepen-
dently associated with the number of MetS components.
We assessed the statistical significance of the relation-
ship using a general linear model with the following
Table 1 Characteristics of subjects categorized by sex
Characteristics Men N = 614 Women N = 779 P -value*
Age (years) 58 ± 14 60 ± 12 0.001
Body mass index (kg/m
2) 23.3 ± 3.0 22.9 ± 3.2 0.027
Smoking status {never/ex/light/heavy (%)} 37.8/20.8/17.9/23.5 97.2/0.8/1.9/0.1 <0.001
Alcohol consumption {never/light/moderate/heavy (%)) 12.2/29.5/34.7/23.6 60.1/33.4/5.9/0.6 <0.001
Systolic blood pressure (mmHg) 135 ± 19 132 ± 22 0.005
Diastolic blood pressure (mmHg) 82 ± 11 78 ± 12 <0.001
Total cholesterol (mg/dL) 191 ± 34 209 ± 33 <0.001
Triglycerides (mg/dL) 97 (71-140) 85 (63-115) <0.001
HDL cholesterol (mg/dL) 58 ± 14 65 ± 15 <0.001
LDL cholesterol (mg/dL) 109 ± 32 124 ± 30 <0.001
Non-HDL cholesterol (mg/dL) 132 ± 34 143 ± 33 <0.001
Total cholesterol/HDL cholesterol ratio 3.45 ± 1.01 3.35 ± 0.92 0.066
Triglycerides/HDL cholesterol ratio 1.67 (1.16-2.74) 1.29 (0.89-1.97) 0.001
LDL cholesterol/HDL cholesterol ratio 2.00 ± 0.81 2.02 ± 0.75 0.601
eGFR 83.9 ± 16.3 82.7 ± 16.5 0.183
Cardiovascular disease, % 5.7 3.9 0.124
HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate. Data presented are mean ± standard deviation. Data for
triglycerides and triglycerides/HDL cholesterol ratio were skewed and were presented as median (interquartile range). Data for triglycerides and triglycerides/HDL
cholesterol ratio were log-transformed for analysis. * Student’s t-test or c
2 test.
Table 2 Insulin resistance and prevalence of metabolic
syndrome of subjects categorized by sex
Characteristics Men
N = 614
Women
N = 779
P
-value*
Metabolic syndrome, % 14.2 8.3 0.001
Fasting blood glucose
(mg/dL)
94 (89-101) 91 (86-97) <0.001
Immuno-reactive insulin
(mU/mL)
4.4 (2.8-7.2) 5.6 (3.8-8.0) <0.001
HOMA-IR§ 1.05 (0.64-1.81) 1.27 (0.84-1.84) <0.001
Serum HMW adiponectin
(μg/mL)
3.20 (1.97-4.92) 6.65 (4.42-9.64) <0.001
HOMA-IR, homeostasis model assessment of insulin resistance; HMW, high
molecular weight. Data for fasting blood glucose, fasting insulin, HOMA-IR, and
serum HMW adiponectin were skewed and presented as median (interquartile
range) values. §HOMA-IR was calculated using the following formula; {fasting
blood glucose (FBG) (mg/dL) X fasting insulin (mU/mL)}/405. Data for fasting
blood glucose, immuno-reactive insulin, HOMA-IR, and serum HMW
adiponectin were log-transformed for analysis. * Student’s t-test or c
2 test.
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hol consumption, SBP, DBP, and eGFR. The interaction
between increased HOMA-IR and reduced serum
HMW adiponectin was a significant and dependent
determinant for the accumulated number of MetS com-
ponents (F = 18.7, P < 0.001), in addition to their direct
association (HOMA-IR, F = 77.0, P < 0.001; serum
HMW adiponectin, F = 9.71, P = 0.002).
Relationship between various risk factors including lipid
profiles and MetS-associated variables categorized by sex
To further investigate whether lipid profiles can explain
the MetS-associated variables independent of other
known confounding factors, multiple linear regression
analyses for the number of MetS components, HOMA-
IR, and serum HMW adiponectin were performed
(Table 3). In both men and women, TG/HDL-C and T-
C/HDL-C ratios as well as TG showed significantly
strong associations with all 3 of the MetS-associated
variables. Non-HDL-C and LDL-C/HDL-C ratio also
showed significant correlations; however almost their b
estimates were lower than the TG/HDL-C ratio.
Comparison of areas under ROC curves (95% CI) for
potential markers of MetS-associated variables of subjects
categorized by sex
In men, the ROC curve analyses showed that the best
marker of the MetS-associated variables (Presence of
MetS, HOMA-IR§ >1.98, and serum HMW adiponectin
<2.97 μg/mL) was TG/HDL-C ratio, with the AUC for
presence of MetS (AUC, 0.82; 95% CI, 0.77-0.87),
HOMA-IR (AUC, 0.75; 95% CI, 0.70-0.80), and serum
HMW adiponectin (AUC, 0.67; 95% CI, 0.63-0.71),
respectively (Table 4). The T-C/HDL-C ratio, TG, HDL-
C, non-HDL-C, and LDL-C/HDL-C ratio also discrimi-
nated these markers; however all their AUC estimates
were lower than the TG/HDL-C ratio. These results
were similar in women. On the other hand, each AUC
of LDL-C for these three variables was near 0.50 in both
women and men.
Discussion
In the present study, we examined whether lipid profiles
(i.e., TG, HDL-C, LDL-C, non-HDL-C, T-C/HDL-C
ratio, TG/HDL-C ratio, and LDL-C/HDL-C ratio) were
Figure 1 Synergistic effect of increased HOMA-IR (homeostasis model assessment of insulin resistance) and reduced serum HMW
(high molecular weight) adiponectin. Mean accumulated number of the following MetS (metabolic syndrome) components: obesity, increased
Blood pressure, impaired fasting glucose, dyslipidemia (hypertriglyceridemia or low high-density lipoprotein cholesterolemia). Study participants
were divided into four groups (quartile) according to HOMA-IR and serum HMW adiponectin levels. Each quartile was calculated within sexes
and then combined to eliminate any gender differences. Statistical significance was assessed by a general linear model for the following
confounding factors: age, sex, BMI, smoking status, alcohol consumption, SBP, DBP, and eGFR.
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HOMA-IR, and serum HMW adiponectin) in Japanese
community-dwelling adults. We demonstrated that
HOMA-IR and serum HMW adiponectin, an active
form of adiponectin, synergistically reflected the accu-
mulated number of MetS components, and TG/HDL-C
and T-C/HDL-C ratios, moreover, TG showed signifi-
cantly and independently strong associations with these
MetS-associated variables in both men and women. The
best marker of three MetS-associated variables was TG/
HDL-C ratio.
Resistance to insulin-mediated glucose disposal is dis-
tributed continuously through the general population
[21], but we have no measurement which identify a par-
ticipant with insulin resistance or insulin sensitive.
Direct measurement of insulin resistance using the
hyperinsulinemic-euglycemic clamp has practical limita-
tions [22]. Some previous studies have shown that
HOMA-IR based insulin resistance measurements have
a strong correlation with glucose clamp-assessed insulin
resistance [18,21]. Although these methods are less
accurate than the hyperinsulinemic-euglycemic clamp,
Table 3 Multiple linear regression analysis of the lipid measures with the number of MetS components, HOMA-IR and
serum HMW adiponectin of subjects categorized by sex
Characteristics b(P-value)
Number. of MetS components HOMA-IR§ Serum HMW adiponectin
Men Women Men Women Men Women
N = 614 N = 779 N = 614 N = 779 N = 614 N = 779
Triglycerides (mg/dL) 0.337 (<0.001) 0.266 (<0.001) 0.237 (<0.001) 0.231 (<0.001) -0.232 (<0.001) -0.237 (<0.001)
HDL cholesterol (mg/dL) -0.193 (<0.001) -0.121 (<0.001) -0.175 (<0.001) -0.122 (<0.001) 0.218 (<0.001) 0.329 (<0.001)
LDL cholesterol (mg/dL) -0.021 (0.503) 0.051 (0.048) 0.091 (0.009) 0.107 (0.001) -0.126 (0.001) -0.176 (0.001)
Non-HDL cholesterol (mg/dL) 0.115 (<0.001) 0.134 (<0.001) 0.164 (<0.001) 0.158 (<0.001) -0.188 (<0.001) -0.227 (<0.001)
Total cholesterol/HDL cholesterol ratio 0.256 (<0.001) 0.201 (<0.001) 0.252 (<0.001) 0.198 (<0.001) -0.295 (<0.001) -0.362 (<0.001)
Triglycerides/HDL cholesterol ratio 0.354 (<0.001) 0.257 (<0.001) 0.258 (<0.001) 0.228 (<0.001) -0.270 (<0.001) -0.315 (<0.001)
LDL cholesterol/HDL cholesterol ratio 0.143 (<0.001) 0.148 (<0.001) 0.209 (<0.001) 0.174 (<0.001) -0.265 (<0.001) -0.352 (<0.001)
MetS, Metabolic syndrome; HOMA-IR, homeostasis model assessment of insulin resistance; HMW, high molecular weight; HDL, high-density lipoprotein; LDL, low-
density lipoprotein. §HOMA-IR was calculated using the following formula; {fasting blood glucose (mg/dL) X immuno-reactive insulin (mU/mL)}/405. Adjusted for
age were BMI, smoking status, alcohol consumption, SBP, DBP, and eGFR. Data for triglycerides, triglycerides/HDL cholesterol ratio, and HOMA-IR were skewed,
and log-transformed for analysis.
Table 4 Comparison of areas under the ROC curves (95% CI) for potential markers of insulin resistance of subjects
categorized by sex
Presence of MetS HOMA-IR§ >1.98 Serum HMW adiponectin <2.97 μg/mL
Characteristics AUC (95% CI) P-value AUC (95% CI) P-value AUC (95% CI) P-value
Men, N = 614
Triglycerides (mg/dL) 0.81 (0.76-0.86) <0.001 0.73 (0.68-0.78) <0.001 0.67 (0.63-0.71) <0.001
HDL cholesterol (mg/dL) 0.28 (0.22-0.34) <0.001 0.31 (0.26-0.36) <0.001 0.40 (0.35-0.44) <0.001
LDL cholesterol (mg/dL) 0.56 (0.50-0.63) <0.001 0.60 (0.54-0.65) <0.001 0.51 (0.47-0.56) 0.577
Non-HDL cholesterol (mg/dL) 0.68 (0.62-0.74) <0.001 0.66 (0.61-0.71) <0.001 0.56 (0.51-0.61) 0.011
Total cholesterol/HDL cholesterol ratio 0.76 (0.70-0.81) <0.001 0.73 (0.68-0.78) <0.001 0.61 (0.56-0.65) <0.001
Triglycerides/HDL cholesterol ratio 0.82 (0.77-0.87) <0.001 0.75 (0.70-0.80) <0.001 0.67 (0.63-0.71) <0.001
LDL-cholesterol/HDL-cholesterol ratio 0.68 (0.62-0.74) <0.001 0.69 (0.63-0.74) <0.001 0.57 (0.53-0.62) 0.002
Women, N = 779
Triglycerides (mg/dL) 0.83 (0.77-0.89) <0.001 0.68 (0.64-0.73) <0.001 0.63 (0.56-0.70) <0.001
HDL cholesterol (mg/dL) 0.25 (0.19-0.32) <0.001 0.38 (0.29-0.39) <0.001 0.28 (0.22-0.34) <0.001
LDL cholesterol (mg/dL) 0.62 (0.54-0.69) 0.021 0.60 (0.56-0.65) <0.001 0.54 (0.47-0.62) 0.218
Non-HDL cholesterol (mg/dL) 0.70 (0.63-0.78) 0.457 0.64 (0.59-0.69) <0.001 0.59 (0.52-0.66) 0.014
Total cholesterol/HDL cholesterol ratio 0.78 (0.72-0.84) <0.001 0.69 (0.65-0.74) <0.001 0.70 (0.63-0.76) <0.001
Triglycerides/HDL cholesterol ratio 0.84 (0.78-0.89) <0.001 0.70 (0.65-0.74) <0.001 0.69 (0.62-0.75) <0.001
LDL cholesterol/HDL cholesterol ratio 0.74 (0.68-0.81) <0.001 0.68 (0.63-0.72) <0.001 0.68 (0.62-0.75) <0.001
ROC, receiver operating characteristics; MetS, metabolic syndrome; HOMA-IR, homeostasis model assessment of insulin resistance; HMW, high molecular weight;
AUC, area under ROC curve; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein. §HOMA-IR was calculated using the following
formula; {fasting blood glucose (mg/dL) X immuno-reactive insulin (mU/mL)}/405. Insulin resistance was defined as values exceeding the fourth quartile of
HOMA-IR, and less than the first quartile of serum HMW adiponectin, respectively.
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normoglycemic individuals [23], but this limitation is
mitigated when the number of subjects evaluated is
large, as in our study [24].Then, we used fasting insulin
and the HOMA-IR as markers of insulin resistance. In
addition, serum adiponectin is also considered to be an
important modulator of insulin sensitivity [25,26] and
dyslipidemia [27]. Thus, we define the cut off value ori-
ginally according to the level of the top quintile of
HOMA-IR distribution and first quartile of serum
HMW adiponectin in our subjects.
T h ep r e s e n c eo fh y p e r t r i g l y c e r i d e m i a ,l o wH D L - C
concentrations, and high TG/HDL-C ratios almost
never occurred as isolated disorders, and were nearly
always associated with insulin resistance because insu-
lin affects TG and HDL-C metabolism [28]. Previous
studies have shown that several lipid ratios have been
proposed as clinically simple and useful indicators of
hyperinsulinemia or insulin resistance. The TG/HDL-C
ratio have shown similar potential for insulin resis-
tance, though the generalizability of this association
has been not entirely consistent. In 50 white Ameri-
cans, both TG and TG/HDL-C ratio were acceptable
markers for insulin resistance, with area under the
ROC curve of 0.763 and 0.770 [29], respectively, and
in a study in an East African population, the TG/HDL-
C ratio was found to be significantly associated with
insulin resistance as measured by HOMA [30]. In con-
trast, recent studies have reported that theTG/HDL-C
ratio was not significantly associated with insulin resis-
tance in black adults [31] and adolescents [32]. The
relationship between TG and TG/HDL-C with insulin
resistance might be shown to differs by ethnicity. In
our Japanese study, both TG/HDL-C and TC/HDL-C
ratios as well as TG were useful makers of MetS-asso-
ciated variables in both men and women, especially
TG/HDL-C ratio in men. However, LDL-C was a
weaker association with these variables. The present
study provides additional information about lipid mea-
sures in both male and female Japanese.
Other lipid profiles have also shown their own rela-
tionship value for MetS. Kimm et al. [33] demonstrated
that the lipid ratios of TC/HDL-C, LDL-C/HDL-C and
TG/HDL-C, as well as TG and HDL-C, were each con-
sistently associated with the number of metabolic syn-
drome components, insulin resistance quartiles (based
on homeostatic model assessment), and log-transformed
adiponectin quartiles. The lipids ratios that include
information on at least two measures might have a
more integrated explanation than single lipid measures
such as TG or HDL-C [33]. In our study, the compar-
able results were seen.
Some limitations of this study must be considered.
First, the response rate was as low as 35% that is usually
the case in other conventional community studies in
Japan. However, the relatively large sample size enabled
the assessment of an extensive array of MetS-associated
variables in relation to lipid profiles. Second, the cross-
sectional study design is limited in its ability to elimi-
nate causal relationships between lipid profiles and
MetS-associated variables. Third, our definition of
HOMA-IR is based on a single assessment of BS and
IRI, which may introduce misclassification bias. Fourth,
we used BMI ≥25 kg/m
2 to classify individuals with visc-
eral obesity because waist circumference measurements
were not available, which might have caused an under
estimation of the effect of visceral obesity on MetS [34].
Therefore the demographics and referral source may
limit generalizability.
In conclusion, the present study demonstrated that
special lipid profiles are associated with MetS-associated
variables in a general population. The ability to identify
who have MetS could help health care professionals in
bringing about lifestyle interventions. In that context,
use of LDL-C/HDL-C ratio or TG/HDL-C ratio
described in this report is simple and useful. Further
prospective population-based studies are needed to
investigate the changes in lipid metabolism by lifestyle
interventions.
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